Introduction
The neutron capture reaction in boron is, in principle, very efficient in killing tum or cells. The two particles emerging from the 10B(n,a)7Li reac tion disperse their combined energy for ionization of 2.34 MeV within a short distance of 4.9 (7Li) and 8.9 |im (4He), corresponding to cellular di mensions, thereby transferring enough energy to lethally damage the cell traversed [1, 2] , Whereas this reaction is used presently to treat brain tum ors [3] , its general applicability to tum or treatm ent is greatly hindered by the unavailability o f boronat ed analogues of tumor-localizing compounds. Such compounds would include antibodies, por phyrins, amino acids, nucleosides, melanin-affinic substances, and hormones [22] , All of these com pounds would be administered systematically, and irradiation procedures could be started only after uptake in the tum or has been established and a sufficient clearance o f boron from the surrounding tissue and especially the blood would be achieved. Thus, suitable boron compounds would have to show a sufficient reten tion time in the target tissue, as well as clear ade quately from the surrounding.
Estrogen-influenced tum ors are found primarily among breast and prostate cancers [4] , Here, breast tum ors sometimes are dependent on estro-R eprint requests to Prof. D. G abel.
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In the past, boron-containing analogues of estrogens and antiestrogens have been suggested repeatedly for use in boron neutron capture thera py. Boronated estrogen derivatives intended for this therapy have been described by Hadd [5] , Kahl [6] , and Sweet [7] , No reports have appeared on their accumulation in cells or in vivo.
Here, we describe the synthesis and biological behavior of a boronated analogue of the antiestro gen U 23,469-M, originally described by Lednicer [8] and Katzenellenbogen [9] , In contrast to estro gens, antiestrogens show a much prolonged up take in the nucleus o f cell in cell culture [10] and in vivo [11] , Thus, it was hoped that a suitable com pound with sufficient cell retention could be ob tained.
The pathway for the synthesis o f the compound (see Scheme 1) followed that described by Lednicer [8] , F or the introduction of the boron moiety, B-decachlorocarborane, originally described by Z akharkin [12] was used. Its anion reacts readily with epoxides [13] . Thus, the easily prepared epoxide I could be opened selectively through a nucleophilic attack at the terminal carbon [13] to yield the desired product III. As described by Katzenellenbogen [9] , the methyl group in the 6-position could be removed selectively.
The binding of this compound to cells in cell cul ture was analyzed by direct boron analysis of the incubated cells [14] . This method allows to analyze for boron down to ppm concentrations, with an error of about 20%. The inhibition o f estradiol up take by U23,469-M and its boronated analogue III was also investigated.
Results and Discussion The stereochemistry of low-molecular weight substances is often of great im portance for their in teraction with their receptors. In III, three chiral carbon atom s are present. As previously Tatee et al. [9] , we have used the racemic mixture of the tetrahydronaphthaline moiety. As racemic epichlorohydrine was used for the introduction of the glycerol side chain, the stereochemistry of the hy droxyl group would be R, S in equal proportions. This is also true for the com pound used by Tatee et al. [9] . N o effort was made to prepare one of the stereoisomers.
The num ber of receptors present in estrogen-receptor containing cells has been estimated to be in the order o f 104 to 105 per cell [15] . For the cells used here, we found a num ber o f 4 x 104 receptors. If only these receptors were used for boron accu mulation, much less than 1 |ig boron per gram cell mass [16] could be obtained. This is far too little for useful neutron capture therapy [17] , where sev eral micrograms per gram would be required for delivering a relevant tum or dose and at the same time-sparing normal tissue.
The non-specific binding of the boronated anti estrogen at concentrations above 10 (imol/1 might accumulate enough boron in cell culture to per form radiobiological experiments. It is doubtful, however, that there might be any differentiation in vivo of tum or and norm al cells, when non-spe cific binding must be used to accumulate boron in a target organ.
In order to increase the binding of boronated antiestrogen analogues, other binding sites than the estrogen receptors might be considered. Sat urable antiestrogen-specific binding sites in the cytosol of horm one-dependent tissues have been described [18] . These antiestrogen binding sites (AEBS) are different from the estrogen receptors insofar as they bind only triphenylethylene anti estrogens. Their natural significance is not yet fully understood. In contrast to the estrogen receptors, the AEBS are not translocated to the nucleus after binding o f the antiestrogen. They are found in estrogen-dependent tum ors and, at relatively high levels, in other tissues o f the rat, e.g. liver, esopha gus, uterus, ovary, and brain [19] . The AEBS found in the microsomal fraction of the human MCF-7 breast carcinom a cell line has a high affini ty (Kd = 0.97 nM) and a narrow specificity for basic triphenylethylene am inoether derivatives. The bas ic aminoether is essential for binding to the AEBS [20] . The antiestrogen U 23,469-M is thus not suit able for binding to AEBS. In order to reach a rela tively high level of boron in estrogen-receptor pos itive tum or cells, a boronated derivative of an anti estrogen with a basic am inoether side chain, like tamoxifen, should be more suitable. However, the number of AEBS found in cells (40,000 [21] to 140,000 [22] for M CF-7 cells and 330,000 for ZR 75-1 cells [23] ) might still be too low for attain ing therapeutically useful boron concentrations.
The synthesis of boronated estrogens and anti estrogens is possible. It must be concluded, how ever, that their accum ulation in estrogen-dependent cells even with retained optimal properties makes them less likely candidates for targeting boron successfully for boron neutron capture therapy.
It should be noted, however, that specific accu m ulation of boron in tum ors has been achieved for other com pounds [27] [28] [29] , thus allowing success ful boron neutron capture therapy to be carried out.
Experimental 'H N M R spectra were recorded on a Bruker W H360, mass spectra on a Finnigan M AT 8222. The mass spectra recorded were in good agreement with the isotope distribution patterns calculated from the natural abundance of chlorine-35 and -37 and b o ro n -10 and -11. Elemental analysis was car ried out by Beller, G öttingen. The results of ele mental analysis of the B-decachloro-o-carborane derivatives described here and of other derivatives were often found not be in good agreement with the calculated values. (p -( 2,3-E poxypropyloxy ) -phenyl) -2-phenyl-6-m ethoxy-l ,2,3,4-tetrahydronaphthalin ( I) A solution of 1.65 g (5 mmol) of l-(/?-hydroxyphenyl-2-phenyl-6-m ethoxy-1,2,3,4-tetrahydronaphthalin [8] in 50 ml freshly distilled epichlorohydrin was refluxed, and water removed with a Dean-Stark trap. When boiling, 5 mmol NaOH as a 20 percent solution in water was added during 30 min. The excess epichlorohydrin was removed in vacuo, the residue was washed with «-hexane and purified by chrom atography on silica gel in petrol ether/acetone 100/15. The colorless oil, still containing solvent, was used directly for the next step.
cis-l-

cis-l-( p -( 3-( Decachloro-o-carboranyl)-2-hydroxylpropyloxy ) -phenyl) -2-phenyl-6-methoxy-1,2,3,4-tetrcihydronaphthalin ( II)
B-decachloro-o-carboran (2.4 g = 5 mmol) was dissolved in 30 ml dry diethyl ether. At 0 °C, an equim olar am ount o f a 15% solution of butyllithium in «-hexane was added dropwise. After 30 min, the cooling mixture was removed and I, dissolved in 20 ml diethyl ether, was added togeth er with 100 ml «-hexane. After 20 h o f stirring at room tem perature, w ater was added and the phases were separated. The aqueous phase was acidified and extracted with diethyl ether. After drying, the ether was removed, and the residue was chrom atographed on silica gel with cyclohexane/ C H2C12 1:1. Yield 72%; m.p. 115-118 °C.
Anal (C28H 28B10C l10O 3) C: calc., 38.42; found 33.40, H, B; Cl: calc. 40.51; found 41. 1 ppm (m, 8 H, phenyl, 1,2,4- c is-l-(p -( 3-( Decachloro-o-carboranyl) 
Cell growth
The hum an breast cancer cell line ZR75-1 [24] , obtained through the American Type Culture Collection, was grown on Petri dishes in RPM I growth medium supplemented with 10 % fetal calf serum, 2 mM glutamin, 10 mg/ml penicillin/strep tomycin. For all cell-binding assays, the cells were grown for 10-14 days in medium supplemented with charcoal-stripped serum [25] , Confluent Petri dishes were incubated at 37 °C for 60 min with tritiated estradiol (AmershamBuchler) at concentrations o f 10"10 to 10~9 m and, when indicated, in the presence of diethylstilbestrol (10-7 m ) as an inhibitor. The cells were exten sively washed with cold phosphate-buffered saline (PBS), trypsinized, and suspended in PBS. The num ber of cells was counted, and the cell suspen sion was counted for tritium in a liquid scintilla tion counter. The num ber of receptors was deter mined from a Scatchard plot.
Cell binding o f boronated antiestrogen
Confluent Petri dishes were incubated with III at concentration of 2 * 10"6 to 10"4 m . After incu bation at 37 °C for 60 min, the cells were washed, trypsinized, resuspended in PBS and counted.
D e te rm in a tio n o f e stro g e n re c e p to rs Boron concentration in the cells was determined according to Gabel [26] and Fairchild [14] .
Inhibition o f estradiol uptake
Confluent Petri dishes were incubated at 37 °C with 1 0~10 m tritiated estradiol, in the presence of diethylstilbestrol, III, and U 23,469-M (the active form of this antiestrogen, containing a free phen olic group) at concentrations between 10"9 and 10"4 m . All other conditions were kept as described above.
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